Quick Answer
BRAINSTORM CELL THERAPEUTICS INC. reported Stockholders Equity of -$9.99 million for the year ending 2025.
- BRAINSTORM CELL THERAPEUTICS INC. showed a decrease of -28.6% in Stockholders Equity from 2024 to 2025.
- This data is from BRAINSTORM CELL THERAPEUTICS INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: $3.48 million | Q2 2013: $2.36 million | Q3 2013: $4.54 million | Q1 2014: $860.0 thousand | Q2 2014: $10.60 million | Q3 2014: $8.90 million | Q1 2015: $19.66 million | Q2 2015: $17.84 million | Q3 2015: $15.52 million | Q1 2016: $12.57 million | Q2 2016: $11.87 million | Q3 2016: $10.53 million | Q1 2017: $8.24 million | Q2 2017: $7.29 million | Q3 2017: $5.20 million | Q1 2018: $3.83 million | Q2 2018: $12.87 million | Q3 2018: $9.98 million | Q1 2019: $326.0 thousand | Q2 2019: -$4.52 million | Q3 2019: -$6.78 million | Q1 2020: $9.01 million | Q2 2020: $9.82 million | Q3 2020: $25.98 million | Q1 2021: $36.20 million | Q2 2021: $30.17 million | Q3 2021: $24.93 million | Q1 2022: $14.49 million | Q2 2022: $7.85 million | Q3 2022: $1.39 million | Q1 2023: -$4.84 million | Q2 2023: -$3.88 million | Q3 2023: -$2.58 million | Q1 2024: -$5.55 million | Q2 2024: -$3.53 million | Q3 2024: -$6.06 million | Q1 2025: -$7.46 million | Q2 2025: -$6.06 million | Q3 2025: -$7.69 million.
- Over the full 18 years of available data (2008 to 2025), BRAINSTORM CELL THERAPEUTICS INC.'s Stockholders Equity has declined by 381.0%.
- Historical annual values: Fiscal year 2025: -$9.99 million | Fiscal year 2024: -$7.76 million | Fiscal year 2023: -$4.86 million | Fiscal year 2022: -$3.02 million | Fiscal year 2021: $19.34 million | Fiscal year 2020: $35.46 million | Fiscal year 2019: -$12.22 million | Fiscal year 2018: $5.02 million | Fiscal year 2017: $5.88 million | Fiscal year 2016: $9.90 million | Fiscal year 2015: $14.13 million | Fiscal year 2014: $6.68 million | Fiscal year 2013: $2.74 million | Fiscal year 2012: $3.98 million | Fiscal year 2011: $1.49 million | Fiscal year 2010: -$459.0 thousand | Fiscal year 2009: -$1.74 million | Fiscal year 2008: -$2.08 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: